Quick Facts: What Sereflo Addresses

Condition	Therapeutic Domain	Primary Benefit
Asthma (Moderate to Severe)	Long-term control	Helps reduce symptoms and frequency of exacerbations
Chronic Obstructive Pulmonary Disease (COPD)	Maintenance treatment	Supports improved airflow and breathing

---

Sereflo is a combination prescription medicine used for the regular maintenance treatment of certain chronic respiratory conditions. It is specifically indicated for patients who may benefit from a combination therapy that includes an inhaled corticosteroid and a long-acting beta-2 agonist.

The medication is used to manage the symptoms of moderate to severe asthma in adult patients and adolescents. It may help reduce the frequency and severity of asthma exacerbations and contributes to long-term control of the condition.

Sereflo is also used as a maintenance treatment to address airflow obstruction associated with Chronic Obstructive Pulmonary Disease (COPD). By addressing the underlying irritation and helping the airways stay open, the medication supports patients in managing their breathing difficulties, such as wheezing and shortness of breath.

It is important to note that Sereflo is a control medication and is not used to relieve acute, sudden episodes of breathlessness.

Eligibility Map: Who Can and Cannot Use Sereflo — Official Regulatory Information

The medicine Sereflo (Fluticasone Propionate/Salmeterol) is governed by regulatory constraints that define specific populations for whom use is allowed, restricted, or strictly prohibited.

---

Populations for whom use is allowed (as stated in label):

• Adults and adolescents aged 12 years and older for the maintenance treatment of asthma.
• Adults for the long-term maintenance treatment of airflow obstruction associated with COPD.
• Patients whose asthma is not adequately controlled on a single long-term control medicine.

Populations for whom use is contraindicated:

• Patients requiring the primary treatment of status asthmaticus or acute episodes of asthma or COPD.
• Patients with a known severe hypersensitivity to the active ingredients or to excipients such as milk proteins (in certain formulations).

Eligibility-Related Restrictions:

• Age Restriction: Use is not recommended for children under 12 years of age in some regulatory regions. Use in children under 4 years is generally not established.
• Comorbidities: Use requires caution in patients with severe cardiovascular disorders, diabetes mellitus, and certain active or quiescent infections (e.g., pulmonary tuberculosis).
• Organ Function: Caution is necessary in patients with severe hepatic impairment due to potential slower clearance, as formal studies are not established. No specific dose adjustment is typically specified for renal impairment.
• Reproductive Status: Use during pregnancy should only be considered if the expected benefit to the mother outweighs the potential fetal risk. A decision to discontinue nursing or discontinue the drug is required during lactation.

---

Connection to the overall eligibility profile:

Regulatory documents strictly prohibit the use of Sereflo for the treatment of acute, sudden symptoms and in patients with known severe allergies. Eligibility is established for adults and adolescents needing chronic maintenance therapy, but use is restricted or conditional in patients with coexisting severe cardiac, metabolic, or liver conditions, or during pregnancy and lactation.

Interactions with other medicines and products

Official regulatory documentation requires caution and/or avoidance when combining Sereflo with specific medicines due to the potential for clinically significant interactions.

---

Interaction Scope

Interaction Classification	Medicinal Products and Categories
Use Not Recommended / Avoid	Strong Cytochrome P450 3A4 (CYP3A4) Inhibitors (e.g., ritonavir, ketoconazole, itraconazole, cobicistat-containing products). Concomitant use with an additional medicine containing a Long-Acting beta2-Agonist (LABA) is required to be avoided.
Use with Caution / Extreme Caution	Beta-blockers (selective and non-selective, e.g., propranolol, atenolol, sotalol). Monoamine Oxidase Inhibitors (MAOIs) and Tricyclic Antidepressants (TCAs). Diuretics (especially non-potassium-sparing types). Xanthine medicines.

---

Practical Interaction Constraints

1. Strong CYP3A4 Inhibitors: These agents may increase the systemic exposure to the active ingredients in Sereflo, raising the risk of systemic corticosteroid effects and cardiovascular effects. Co-administration is formally not recommended.
2. Beta-blockers: Both non-selective and selective beta-blockers may antagonize or weaken the bronchodilatory effects of the salmeterol component. Due to the risk of severe bronchospasm, their use requires caution and is to be avoided unless there are compelling clinical reasons.
3. MAOIs and TCAs: These products should be used with extreme caution, as they may potentiate the effect of salmeterol on the vascular system.
4. Diuretics and Xanthines: Caution is advised with non-potassium-sparing diuretics and xanthine derivatives, as the risk of hypokalaemia and related electrocardiographic changes may be worsened with the concomitant use of beta2-agonists.

The combination product Sereflo operates across two fundamental biological domains: sustained muscle tone regulation and genomic control of inflammation, utilizing the distinct yet complementary mechanisms of its two active ingredients.

---

Sustained Bronchial Muscle Relaxation

This domain is driven by Salmeterol, which acts as a long-acting partial agonist on beta2-Adrenergic Receptors (beta2-ARs) found on airway smooth muscle cells. The activation of these receptors triggers a cellular cascade that increases cAMP levels, leading to the inactivation of key contractile proteins. This molecular sequence produces the physiological consequence of sustained muscle relaxation, which contributes to the prolonged maintenance of bronchial lumen diameter.

---

Genomic Modulation of Airway Inflammation

This mechanism is mediated by Fluticasone Propionate, which binds to the cytoplasmic Glucocorticoid Receptor (GR) and modulates gene transcription. By a process called transrepression, the Fluticasone-GR complex effectively blocks the synthesis of pro-inflammatory proteins (like certain cytokines and chemokines). This action results in the long-term suppression of chronic inflammatory processes in the airway tissue and establishes a physiological state characterized by reduced airway tissue hyperreactivity.

---

Mechanistic Receptor Complementarity

The two components exhibit complementary pharmacodynamic mechanisms: Fluticasone Propionate mechanistically enhances the responsiveness and may increase the expression of the beta2-ARs. This cross-talk modulates the function of beta2-ARs, contributing to the mitigation of receptor desensitization. The interaction supports the sustained physiological function of the bronchodilator component.

Administration Guidelines

Sereflo (Salmeterol/Fluticasone Propionate) is a combination product strictly intended for regular maintenance treatment and must be administered by the orally inhaled route only, using either a Pressurized Inhalation Suspension (MDI) or an Inhalation Powder (DPI). It is not indicated for the relief of acute, sudden episodes of bronchospasm or breathlessness.

---

Dosage and Schedule

The medicine must be used twice daily, every day, for optimal benefit, with doses administered approximately 12 hours apart (morning and evening). The specific dose strength (e.g., 25/125 mug, 25/250 mug, or 50/500 mug) and the number of inhalations are determined by the treating physician and should not exceed the maximum labeled dosage of the highest strength twice daily. Once control of the condition is attained, the dose is recommended to be titrated downwards to the lowest effective dose. Use is generally approved for adults and adolescents aged 12 years and older, though specific MDI strengths may be restricted to those 18 years and older.

---

Procedural Use Instructions

Immediately after inhaling the dose, the standard administration procedure includes patients to rinse their mouth with water and spit it out without swallowing. If a scheduled dose is missed, standard practice is to skip the missed dose and take the next dose at the regular time; the dose should not be doubled to compensate. The therapy must not be stopped abruptly; any discontinuation or change in dosage must be supervised by a healthcare professional.

Research Evidence / Overview of Studies for Sereflo

---

Evidence for Use in Managing Asthma

The research conducted on Sereflo, the combination of Salmeterol and Fluticasone Propionate, primarily consists of Randomized Controlled Trials (RCTs). These studies were used in research exploring how symptoms change over time and were conducted to compare the observed outcomes when the two components are used together versus when either component is used alone, or an inactive device (placebo).

In these studies, the primary focus was on measuring functional parameters like FEV1 (Forced Expiratory Volume in 1 second) and PEF (Peak Expiratory Flow). Research also examined outcomes related to episodic or acute changes, such as how often patients reported using a rescue inhaler, and the frequency of exacerbation events. The populations studied were mainly adults and adolescents who already had persistent symptoms despite receiving existing inhaled corticosteroid therapy.

---

Evidence for Use as Maintenance Therapy for COPD

The evidence base for Sereflo's use as a maintenance treatment for Chronic Obstructive Pulmonary Disease ( COPD) is established through a number of large-scale clinical trials, including studies that were conducted over several years. These studies were applied in research contexts involving fluctuating or unstable symptoms typical of the condition.

For COPD, the research particularly focused on outcomes capturing phases of heightened symptom activity, primarily the annual rate of moderate and severe exacerbations (flares) that require treatment changes. Studies observed and reported differences in the rate of exacerbation events and changes in scores on health status questionnaires when comparing the combination to placebo or single-component regimens. This research provides insight into short-term changes and contributes to the broader evidence landscape for long-term respiratory stability.

---

Consistency of Evidence and Areas of Uncertainty

Research explored the combination's association with measured changes in functional measures in asthma and with the rate of exacerbation events in severe COPD. The results reported in some studies were consistent with one another.

Despite the available evidence, certainty remains low in certain areas. For instance, long-term effects are not fully established beyond the observation periods of the key trials. Furthermore, research is still exploring whether the combination of the two components is associated with variations in study measures compared to using only the inhaled corticosteroid component at higher doses in all asthma cases. This means the evidence highlights what is known and what is still uncertain.

Key Studies & References

1. Pharmacokinetic and Pharmacodynamic (PK and PD) Study of Fluticasone Propionate and Salmeterol Combination Product in Moderate Asthma Patients and Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
2. Global Strategy for Asthma Management and Prevention (GINA) Report (Used for context on guidelines/study populations)

Common questions about Sereflo (FAQ)

Q: Does Sereflo replace my rescue inhaler?

According to official product information, Sereflo is strictly designed for regular, long-term maintenance and is not indicated for sudden, acute breathing problems or bronchospasm. Regulatory information consistently emphasizes that patients are required to have a separate, fast-acting inhaler for the treatment of immediate symptoms.

Q: Does Sereflo start working right away?

Sereflo is a combination of a long-acting bronchodilator and an inhaled corticosteroid. It is formulated to provide sustained control over time, rather than immediate symptom relief. Regulatory warnings note that the medicine is not intended for use in acute symptoms.

Q: What is the difference between Sereflo and the other inhalers I see advertised?

Sereflo is a fixed-dose combination product containing two active ingredients: a long-acting beta-agonist (LABA) and an inhaled corticosteroid (ICS). This dual-component approach addresses both muscle relaxation and underlying inflammation. This design is for long-term maintenance, which differs from single-ingredient or short-acting rescue inhalers.

Q: How long does it take before the full effects of Sereflo are felt?

The medicine is for long-term control. Because the inhaled corticosteroid component works gradually to address inflammation, the full benefits of this type of maintenance therapy may take one to two weeks or longer to become apparent, according to evidence from supporting studies.

Q: Does Sereflo cause weight gain?

Regulatory safety documentation lists potential systemic effects associated with the inhaled corticosteroid component, such as very rare instances of Cushing’s syndrome and metabolic changes. However, weight gain itself is not specifically documented as a common or uncommon side effect in the medicine's official safety profile.

Q: Is it normal to feel shaky after using Sereflo?

Official regulatory safety data lists tremor (shakiness) as an uncommon adverse reaction. This effect is associated with the long-acting beta-agonist (LABA) component of Sereflo.

Q: Can using Sereflo make me feel anxious or nervous?

Official regulatory safety information notes that anxiety is an uncommon adverse reaction. This is considered a systemic effect that has been noted in the medication’s safety profile.

Q: Is Sereflo known to interact with common pain relievers like ibuprofen?

Official documentation provides specific warnings for interactions with medicines like beta-blockers, certain antidepressants, and strong CYP3A4 inhibitors. Official documentation does not list non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen among the classes of medicines that require an official warning for clinically significant interaction with Sereflo.

Q: Are there specific foods or drinks that should be avoided while using Sereflo?

Official product labeling does not provide a list of common foods or drinks that are required to be avoided. However, regulatory warnings exist for medicines that are strong inhibitors of the CYP3A4 enzyme, as these can potentially increase exposure to the drug.

Q: Will Sereflo affect my sleep?

Official regulatory safety information lists potential adverse reactions that may affect sleep, including insomnia and anxiety. These are considered systemic effects that may occur.

Q: Does Sereflo have any black box warnings from the FDA or similar agencies?

Yes, the product information contains a prominent Boxed Warning issued by the FDA. This warning concerns the long-acting beta-agonist (LABA) component, Salmeterol, which is associated with an increased risk of asthma-related death or hospitalization, as noted in official regulatory documents.

Q: Is Sereflo available over-the-counter anywhere?

Sereflo is classified by regulatory agencies as a prescription-only medicine (POM). It is not authorized for purchase without a medical prescription in any major regulatory region.

Q: Does Sereflo contain lactose or any other common allergens?

The official product label states that the dry powder inhaler (DPI) formulation contains lactose as an inactive ingredient. Furthermore, certain formulations may contain trace amounts of excipients derived from milk proteins. This information is relevant for patients with known severe hypersensitivity.

Q: Can Sereflo cause problems with bone density?

Regulatory documents include warnings about the potential systemic effects associated with the long-term use of inhaled corticosteroids. These warnings mention the possibility of changes in bone mineral density (BMD).

Q: Do any official warnings exist about taking Sereflo with alcohol?

Official regulatory documents regarding Sereflo do not list a specific warning or contraindication related to the consumption of alcohol.

Q: Why might a doctor switch a patient from one inhaler to Sereflo?

Official indications state that Sereflo is intended for patients whose asthma or COPD is not adequately controlled when using a single long-term control medicine (such as an inhaled corticosteroid alone). The combination therapy is introduced to address the need for both bronchodilation and anti-inflammatory action in one device.

Q: What is the difference between the low, medium, and high strengths of Sereflo?

The low, medium, and high strengths of Sereflo refer to the varying quantities of the active ingredients (Salmeterol and Fluticasone Propionate) delivered with each inhalation. These strengths are identified on the official label by the different micrograms (mu g) listed.

Q: What kind of studies have been done on Sereflo's long-term safety?

The evidence base for Sereflo includes large-scale clinical trials used to assess efficacy and safety. These studies have observation periods that can extend for up to several years, providing insight into how the medication affects functional measures and the rate of acute events over time.

Q: How long can a person stay on Sereflo treatment?

Sereflo is indicated for the long-term maintenance treatment of chronic airway conditions. Regulatory information generally advises that once control of the condition is attained, the dose should be titrated downwards to the lowest effective maintenance dose.

Q: Does Sereflo affect blood sugar levels?

Official safety information states that hyperglycemia (high blood sugar) is listed as an uncommon adverse reaction. This is associated with the systemic effects of the medication.

Q: Can Sereflo affect the eyes or vision?

Yes, official safety data lists the potential for cataracts and glaucoma (increased pressure in the eye) as adverse reactions. These effects are associated with the systemic absorption of the inhaled corticosteroid component.

How to Store and Dispose of Sereflo?

• Storage Conditions: Store Sereflo below 25 C in a dry place. The medicine must be protected from direct heat, sunlight, and frost, as it may not work as effectively when cold. Do not store the pressurized canister above 50 C.

• Handling: The canister is pressurized. Do not pierce or burn the container, even when it is empty, and do not remove it from the plastic casing for cleaning. Keep this medicine out of the sight and reach of children.

• Disposal: Do not use Sereflo after the expiry date printed on the packaging. If the medicine is expired or no longer needed, return the canister to your pharmacist for proper disposal. Do not dispose of the medicine via household waste.